SCHEMBL1593401

SCHEMBL1593401

Cc1ccc(S(=O)(=O)n2nc(I)c3cc(N)ccc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
KMT2A Q03164 10/20 0.45
MEN1 O00255 6/20 0.45
ALDH1A1 P00352 4/20 0.43
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
GAA P10253 2/20 0.42
POLB P06746 1/20 0.41
SLC9A1 P19634 1/20 0.40
KDM4E B2RXH2 2/20 0.39
CXCL8 P10145 1/20 0.39
NOD2 Q9HC29 1/20 0.39
NOD1 Q9Y239 1/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
PKM P14618 1/20 0.38
F2 P00734 1/20 0.38
CTSB P07858 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1593717 0.84 MAPT (0.51) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL26863195 0.81 MAPT (0.49) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL1099865 0.78 MAPT (0.57) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL26863192 0.76 MAPT (0.45) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL31617556 0.74 MAPT (0.42) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL1272497 0.70 MAPT (0.50) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL29507323 0.70 MAPT (0.44) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL4724446 0.70 MAPT (0.50) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL3470562 0.70 MAPT (0.47) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL12253486 0.69 SLC9A1 (0.56) MAPTKMT2AMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394795-B2 Pyrazole [3, 4-B] pyridine Raf inhibitors ARRAY BIOPHARMA INC. (US) 2013-03-12 US disclosed
EP-2265610-B1 PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC (US) 2012-12-12 EP disclosed
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-04-21 US disclosed
EP-2265610-A1 PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS Array Biopharma, Inc. (US) 2010-12-29 EP disclosed
WO-2009111279-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS BRAF, RAF1, ARAF MAPT 946/4885KMT2A 3704/4885MEN1 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.